Thanks for joining us as we presented new prospective data about EGFR and molecular risk stratification in early-stage NSCLC, followed by an engaging panel discussion with lung cancer experts. Click on the Right for the Webinar Recording. Summary of New Data: In a 250-patient ...

In Case you Missed our Live Webinar Featuring Dr. Naoto Ueno of the MD Anderson Cancer Center We discussed exciting data from MD Anderson and how DetermaIO utilizes the Tumor Micro-Environment to achieve better predictive value than PD-L1 and TMB. Click HERE for the Recording ...

San Francisco, CA – May 6, 2020 – Winners of Cofactor Genomics’ “Functional to FFPE” Grant Program were publicly announced today. Two projects from Dell Medical School at University of Texas and the University Hospital in Basel were chosen based on their potential to make a s...

Burlingame, Calif., April 29, 2020 --- Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, announced the publication of a health economic model that shows the use of the company’s HostDxTM Sepsis test in patients suspecte...

Burlingame, Calif., April 16, 2020 --- Inflammatix, a pioneering molecular diagnostics company delivering precision medicine at the point of care, today announced the appointment of João Fonseca, Ph.D., as Chief Technology Officer. Dr. Fonseca will oversee Inflammatix’s molecu...

The leadership of Quara Devices, Rod Reum, Executive Chairman, Ken Reardon Ph.D., CSO, and Steven Eror, CEO revealed more about their ongoing work developing an exciting new weapon to help in the fight against superbugs. These bacteria, with their resistance to several antibio...

Boston, MA -- September 26, 2019 -- Today Cofactor Genomics announced that it has expanded the leadership team with the promotion of Natalie LaFranzo, PhD to Vice President of Market Development. Dr. LaFranzo’s amplified leadership role includes clinical collaboration manageme...